Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 53.23% is in line with its 5-year average of 56.88%, near the low end of its 5-year range (48.16%–66.36%).
0.45% above its 12-month average of 52.99%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 58.87%.
GROSS MARGIN
53.23%
GROSS MARGIN AVG TTM
52.99%
GROSS MARGIN AVG 3Y
54.18%
GROSS MARGIN AVG 5Y
56.88%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.45%
CURRENT VS 3Y AVG
-1.76%
CURRENT VS 5Y AVG
-6.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 598 covered companies
CURRENT VS SECTOR MEDIAN
+24.05%
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$744.51M
Gross Margin
53.23%
TTM Avg
52.99%
3Y Avg
54.18%
5Y Avg
56.88%
Market Cap
$743.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$748.55M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$755.39M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
Market Cap
$722.78M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
Market Cap
$712.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$766.58M
Gross Margin
65.99%
TTM Avg
63.07%
3Y Avg
62.20%
5Y Avg
62.16%
Market Cap
$768.46M
Gross Margin
98.85%
TTM Avg
98.73%
3Y Avg
-10570.46%
5Y Avg
-10093.61%
Market Cap
$773.03M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $744.51M | 53.23% | 52.99% | 54.18% | 56.88% |
| Candel Therapeutics, Inc. (CADL)vs › | $743.69M | 0.00% | 0.00% | 25.00% | 50.00% |
| Design Therapeutics, Inc. (DSGN)vs › | $748.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.39M | 40.44% | 20.22% | 20.22% | 20.22% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $722.78M | 100.00% | 141.50% | 99.31% | 94.19% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $712.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mesa Laboratories, Inc. (MLAB)vs › | $766.58M | 65.99% | 63.07% | 62.20% | 62.16% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | 98.85% | 98.73% | -10570.46% | -10093.61% |
| Geron Corporation (GERN)vs › | $773.03M | 97.42% | 97.90% | 98.95% | -3197.94% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $703.70M | 60.02% | 59.55% | 55.45% | 55.70% |
Gross Margin
53.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 58.87% |
| 2026-03-31 | 48.16% |
| 2025-12-31 | 52.92% |
| 2025-09-30 | 52.69% |
| 2025-06-30 | 52.34% |
| 2025-03-31 | 48.62% |
| 2024-12-31 | 58.55% |
| 2024-09-30 | 56.32% |
| 2024-06-30 | 54.56% |
| 2024-03-31 | 51.30% |
| 2023-12-31 | 56.75% |
| 2023-09-30 | 56.62% |
| 2023-06-30 | 56.67% |
| 2023-03-31 | 56.72% |
| 2022-12-31 | 60.77% |
| 2022-09-30 | 66.36% |
| 2022-06-30 | 61.16% |
| 2022-03-31 | 57.54% |
| 2021-12-31 | 60.77% |
| 2021-09-30 | 61.89% |
| 2021-06-30 | 64.93% |
| 2021-03-31 | 59.68% |
| 2020-12-31 | 63.52% |
| 2020-09-30 | 62.23% |
| 2020-06-30 | 43.22% |
| 2020-03-31 | 46.56% |
